Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockCJC-1295 No DAC
Third-Party TestedPurity Standards
Total
$19.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Type
Synthetic peptide (tetrasubstituted, 29 residues)
Molecular formula
C152H252N44O42
Molecular weight
~3,368 g/mol
CAS number
863288-34-0
Amino acids
29
Sequence
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Modification
Tetrasubstituted GRF(1-29) (D-Ala2, Gln8, Ala15, Leu27); C-terminal amide. The substitutions are positioned to resist DPP-IV cleavage, asparagine deamidation, and methionine oxidation. Unlike the DAC variant, it lacks the C-terminal albumin-binding maleimidopropionyl group.
Mechanism & Target Class
Mechanism & Target Class
A 29-residue synthetic peptide corresponding to the N-terminal fragment (residues 1-29) of a 44-residue hypothalamic peptide, studied structurally in the context of class B1 G-protein-coupled receptor complexes. Four substitutions relative to the native fragment — D-Ala2, Gln8, Ala15, and Leu27 — confer greater enzymatic and chemical stability against DPP-IV cleavage, asparagine deamidation, and methionine oxidation. Because it lacks the DAC variant's albumin-binding group, it is short-circulating rather than long-circulating.
Storage & Handling
Storage & Handling
Lyophilized
20°C
lyophilized peptide stored desiccated and protected from light.
Aliquot to avoid repeated freeze-thaw; protect from light and moisture. Storage conventions reflect supplier guidance for lyophilized peptides of this class.
References
References
Reviews
- 1
Halmos G, et al. (2023). Vitamins and Hormones
- 2
Campbell RM, Bongers J, Felix AM. (1995). Biopolymers
Reviews
- 3
Schally AV, et al. (2019). Endocrinology
Clinical
- 4
Sackmann-Sala L, et al. (2009). Growth Horm IGF Res
- 5
Teichman SL, et al. (2006). J Clin Endocrinol Metab
- 6
Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab
- 7
ClinicalTrials.gov registry. ClinicalTrials.gov
- 8
Chen RG, et al. (1993). Acta Paediatr Suppl
- 9
Neyzi O, et al. (1993). Acta Paediatr Suppl
Primary research
- 10
Zhou F, et al. (2020). Nat Commun
- 11
Cai R, Schally AV, et al. (2014). Peptides
- 12
Alba M, et al. (2006). Am J Physiol Endocrinol Metab
- 13
Jetté L, et al. (2005). Endocrinology
- 14
Dubreuil P, et al. (2001). Growth Horm IGF Res
- 15
Izdebski J, et al. (1995). Proc Natl Acad Sci USA
- 16
Bongers J, et al. (1992). Int J Pept Protein Res
- 17
Friedman AR, et al. (1991). Int J Pept Protein Res
- 18
Frohman LA, et al. (1989). J Clin Invest
- 19
Lance VA, et al. (1984). Biochem Biophys Res Commun
- 20
Stevenson CL, et al.. PubMed
- 21
Cui T, et al. (2018). Oncotarget
Primary Database
Primary Database
Also known as: Modified GRF (1-29), Mod GRF (1-29), Tetrasubstituted GRF (1-29), CJC-1295 without DAC
View this compound in the Research Library →Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
